

Abstracts accepted for Oral Presentations

#183

Topic: *AS02 CURRENTLY ONGOING CLINICAL TRIALS***PHASE 1/2 MULTICENTER CLINICAL TRIAL OF DONOR SPECIFIC TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION VIA ENGINEERED T CELLS WITH SUPPRESSING FUNCTIONS**

Y. Maehara, K. Uchida, K. Takeda, K. Okumura
Juntendo University, Center For Immunotherapy And Diagnosis, Juntendo Daigaku Igakubu
Daigakuin Igaku Kenkyuka, Tokyo, Japan

#184

Topic: *AS02 CURRENTLY ONGOING CLINICAL TRIALS***GD2.CAR T-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR FOR TREATMENT OF PEDIATRIC CNS TUMORS**

B. Omer¹, F. Lin¹, A. Stuckert¹, C. Rooney²
¹Baylor College of Medicine, Pediatric Hematology/oncology, Houston, United States of America, ²Baylor College of Medicine, Cell And Gene Therapy, Houston, United States of America

#148

Topic: *AS03 NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES***COMBINATION OF TCR-T CELLS COENGINEERED TO SECRETE SIRP-ALPHA DECOYS AND ANTI-TUMOR ANTIBODIES TO AUGMENT MACROPHAGE PHAGOCYTOSIS**

E. Stefanidis¹, A. Semilietof^{1,2}, J. Pujol¹, B. Seijo¹, K. Scholten¹, V. Zoete^{1,2}, O. Michielin^{1,2,3}, R. Sandaltzopoulos⁴, G. Coukos¹, M. Irving¹
¹Ludwig Institute for Cancer Research, University of Lausanne and Lausanne University Hospital, Department Of Oncology, Lausanne, Switzerland, ²Swiss Institute of Bioinformatics, Department Of Oncology, Epalinges, Switzerland, ³University Hospital of Geneva, Department Of Oncology, Geneva, Switzerland, ⁴Democritus University of Thrace, Department Of Molecular Biology And Genetics, Alexandroupolis, Greece

#143

Topic: *AS04 SUPERPOWERED LYMPHOCYTES***EMPOWERING CYTOTOXICITY OF CAR T CELLS TO ENHANCE ANTI-CANCER RESPONSES**

V. Peperzak, T. Kimman, M. Cuenca, Z. Sebestyen
UMC Utrecht, Center For Translational Immunology, Utrecht, Netherlands

#160

Topic: *AS05 NON-VIRAL CAR/TCR ENGINEERING***PERSISTENT GENETIC MODIFICATION OF HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS USING S/MAR DNA NANOVECTORS**

P. Derigs^{1,2}, A. Roig-Merino³, J. Peterson¹, L. Burger¹, T. Tasgin¹, A. Hartley¹, M. Schmitt², C. Müller-Tidow², R. Harbottle¹

¹German Cancer Research Center, Dna Vector Lab, Heidelberg, Germany, ²University Hospital Heidelberg, Department of Internal Medicine V, Heidelberg, Germany, ³MaxCyte, Inc., Gaithersburg, United States of America

#156

Topic: *AS06 UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING***REDIRECTING TCR SPECIFICITY IN REGULATORY T CELLS TOWARD CLASS I HLA-RESTRICTED ISLET ANTIGENS**

R. Porret¹, P. Guillaume², O. Alfageme-Abello¹, A. Alcaraz Serna¹, L. Ermellino¹, E. Lana¹, E. Stefanidis², A. Semilietof², G. Giordano Attianese², F. Lebreton³, V. Zoete⁴, E. Berishvili³, M. Irving², Q. Tang⁵, Y. Muller¹

¹Centre Hospitalier Universitaire Vaudois (CHUV), Division Of Immunology And Allergy, Lausanne, Switzerland, ²Ludwig Institute for Cancer Research, University of Lausanne and Lausanne University Hospital, Department Of Oncology, Lausanne, Switzerland, ³Geneva University Hospitals (HUG), Cell Isolation And Transplantation, Geneva, Switzerland, ⁴Swiss Institute of Bioinformatics/ Ludwig Institute for Cancer Research, Department Of Oncology, Epalinges, Switzerland, ⁵University of California (UCSF), Diabetes Center, San Francisco, United States of America

#102

Topic: *AS07 BEYOND ALPHA-BETA T CELLS***TCR-ENGINEERED INKT CELLS INDUCE ROBUST ANTI-TUMOR RESPONSE BY DUAL TARGETING CANCER AND SUPPRESSIVE MYELOID CELLS**

G. Delfanti¹, F. Cortesi¹, A. Perini¹, L. Azzimonti², C. De Lalla¹, C. Garavaglia¹, M. Squadrito³, M. Consonni¹, F. Re⁴, H. Shen⁵, P. Dellabona¹, G. Casorati¹

¹San Raffaele Scientific Institute, Experimental Immunology Unit, Division Of Immunology, Transplantation And Infectious Diseases, Milan, Italy, ²IDSIA, Supsi/usi, Manno, Switzerland, ³San Raffaele Telethon Institute for Gene Therapy (SRTIGET), Targeted Cancer Gene Therapy Unit, Milan, Italy, ⁴School of Medicine and Surgery, University of Milano- Bicocca, Bionanomedicine Center Nanomib, Monza, Italy, ⁵Houston Methodist Research Institute, Department Of Nanomedicine, Houston, United States of America

#131

Topic: *AS08 IN VIVO T CELL ENGINEERING***MULTI-OMICS INFORMED ENHANCEMENT OF CAR GENE DELIVERY BY RAPAMYCIN, INDUCED REDUCTION OF ANTIVIRAL MECHANISMS AGAINST T-CELL TARGETED LENTIVIRAL VECTORS**

F. Charitidis¹, E. Adabi¹, N. Ho¹, A. Braun^{1,2}, C. Tierney³, L. Strasser³, F. Thalheimer^{1,4}, L. Childs⁵, J. Bones^{3,6}, C. Clarke^{3,7}, C. Buchholz^{1,2,4}

¹Molecular Biotechnology and Gene Therapy, Paul-ehrlich-institut, Langen (Hessen), Germany, ²Deutsches Krebsforschungszentrum and German Cancer Consortium, (dktk), Heidelberg, Germany, ³Characterisation and Comparability Laboratory, National Institute For Bioprocessing Research And Training, Dublin, Ireland, ⁴Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany, ⁵Host-Pathogen Interactions, Paul-ehrlich-institut, Langen (Hessen), Germany, ⁶School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin, Ireland, ⁷National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Dublin, Ireland

#130

Topic: *AS09 TARGETING NON-MALIGNANT DISEASES***MRNA TECHNOLOGY FOR THE DEVELOPMENT OF CAR-T CELLS TARGETING FIBROTIC DISEASES**

S. Bräuning^{1,2}, R. Kitte¹, C. Möser^{1,2}, D. Schiefer¹, S. Greiser^{1,2}, S. Fricke^{1,2}, U. Köhl^{2,3,4}, S. Tretbar^{1,2}, U. Blache^{1,2}

¹Fraunhofer Institute for Cell Therapy and Immunology IZI, Cell And Gene Therapy Development, Leipzig, Germany, ²Fraunhofer Cluster of Excellence Immune-Mediated Diseases, Cimd, Leipzig, Germany, ³Fraunhofer Institute for Cell Therapy and Immunology IZI, Institute's Director, Leipzig, Germany, ⁴Institute for Clinical Immunology, Medical Faculty, University Of Leipzig, Leipzig, Germany

#52

Topic: *AS09 TARGETING NON-MALIGNANT DISEASES***SELECTIVE DEPLETION OF ALLOREACTIVE B CELLS IN SOLID ORGAN TRANSPLANTATION: CHIMERIC ALLO-ANTIGEN-SPECIFIC T CELLS OVERCOMING REJECTION BY ANTIBODIES (CORA-TS)**

A.C. Dragon¹, A. Bonifacius¹, S. Lienenklaus², M. Verboom¹, R. Taubert³, F. Ius⁴, M. Hudecek⁵, C. Ferreira De Figueiredo¹, R. Blasczyk¹, B. Eiz-Vesper¹

¹Hannover Medical School (MHH), Institute Of Transfusion Medicine And Transplant Engineering, Hannover, Germany, ²Hannover Medical School (MHH), Institute Of Laboratory Animal Science, Hannover, Germany, ³Hannover Medical School (MHH), Department Of Gastroenterology, Hepatology And Endocrinology, Hannover, Germany, ⁴Hannover Medical School (MHH), Department Of Cardiothoracic, Transplant And Vascular Surgery, Hannover, Germany, ⁵University Hospital of Würzburg, Department Of Internal Medicine Ii, Würzburg, Germany

#181

Topic: *AS10 OTHER***DEVELOPING NOVEL TARGETING CARs FOR GLIOBLASTOMA**

R. Abbott¹, M. Iliopoulos¹, K. Watson², V. Arcucci¹, H. Hughes-Parry², P. Smith³, M. Call⁴, R. Cross¹, M. Jenkins¹

¹Walter and Eliza Hall Institute of Medical Research, Immunology, Parkville, Australia, ²WEHI Medical Research, Immunology, Parkville, Australia, ³Myrio Therapeutics, Myrio, Melbourne, Australia, ⁴Walter and Eliza Hall Institute of Medical Research, Structural Biology, Parkville, Australia

#180

Topic: *AS10 OTHER***INFECTED HEPATOCYTE CLEARANCE AND SUSTAINED TUMOR REGRESSION BY HBSAG-SPECIFIC TCR-T THERAPY FOR HBV-RELATED HCC**

S. Du¹, K. Wisskirchen^{2,3}, X. Wan¹, X. Wu¹, F. Liu¹, Y. Wu¹, K. Zhang⁴, U. Protzer^{3,5}

¹Peking Union Medical College Hospital, Department Of Liver Surgery, Beijing, China, ²SCG Cell Therapy GmbH, R&d, Planegg, Germany, ³Helmholtz Munich, Institute Of Virology, Munich, Germany, ⁴SCG Cell Therapy, R&d, Shanghai, China, ⁵Technical University of Munich, Institute Of Virology, Munich, Germany